Medical cannabis: Critical points for clinical application
Abstract
Since ancient times cannabis has been used for recreational and medicinal purposes. It is a significant source of chemical compounds, most of them called phytocannabinoids. These compounds have several physiological effects and produce their effects primarily by binding to endogenous cannabinoid receptors such as CB1 and CB2, among others.
Cannabis has potential therapeutic properties and its preparations have been used as traditional remedies to treat pain and emesis. Synthetic cannabinoids are used clinically as analgesics, antispastics, antiemetics, and appetite stimulants. Significant cannabis toxicity is rare in adults; however, it can produce countless acute and chronic side effects.
The quality of the evidence in this field is limited by the short duration of the trials, poor sample sizes, lack of a control group, and the existence of bias in most of the reviewed studies. Therefore, a larger number of studies with better methodological quality is required to support the safe use of this therapy. The decision to include cannabinoids as a treatment for any of the conditions described will depend on the evidence, the use of previous therapies, and the type of patient.
Downloads
References
Breijyeh Z, Jubeh B, Bufo SA, Karaman R, Scrano L. Cannabis: A toxin-producing plant with potential therapeutic uses. Toxins (Basel). 2021;13:117. https://doi.org/10.3390/toxins13020117
Ramos JA. Efectos terapéuticos de los Cannabinoides. Madrid: Instituto Universitario de Investigación en Neuroquímica de la Universidad Complutense de Madrid; 2017. p. 31-2.
Stasiulewicz A, Znajdek K, Grudzień M, Pawiński T, Sulkowska JI. A guide to targeting the endocannabinoid system in drug design. Int J Mol Sci. 2020;21:2778. https://doi.org/10.3390/ijms21082778
Fraguas-Sánchez AI, Torres-Suárez AI. Medical use of Cannabinoids. Drugs. 2018;78:1665-703. https://doi.org/10.1007/s40265-018-0996-1
Abrams DI. Integrating cannabis into clinical cancer care. Curr Oncol. 2016;23:S8-14. https://doi.org/10.3747/co.23.3099
National Academies of Sciences, Engineering and Medicine. The health effects of cannabis and cannabinoids: The current state of evidence and recommendations for research. Washington (DC): National Academies Press (US); 2017. https://doi.org/10.17226/24625
Beal JE, Olson R, Laubenstein L, Morales JO, Bellman P, Yangco B, et al. Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. J Pain Symptom Manage. 1995;10:89-97. https://doi.org/10.1016/0885-3924(94)00117-4
Russo M, Naro A, Leo A, Sessa E, D’Aleo G, Bramanti P, et al. Evaluating Sativex® in neuropathic pain management: A clinical and neurophysiological assessment in multiple sclerosis. Pain Med. 2016;17:1145-54. https://doi.org/10.1093/pm/pnv080
Friedman D, Devinsky O. Cannabinoids in the treatment of epilepsy. N Engl J Med. 2015;373:1048-58. https://doi.org/10.1056/NEJMra1407304
Thiele E, Bebin E, Bhathal H, Jansen E, Kotulska K, Lawson JA, et al. Add-on cannabidiol treatment for drug-resistant seizures in tuberous sclerosis complex: A placebo-controlled randomized clinical trial. JAMA Neurol. 2021;78:285-92. https://doi.org/10.1001/jamaneurol.2020.4607
Devinsky O, Patel A, Cross J, Villanueva V, Wirrell EC, Privitera M, et al. Effect of cannabidiol on drop seizures in the Lennox–Gastaut syndrome. N Engl J Med. 2018;378:1888-97. https://doi.org/10.1056/NEJMoa1714631
Devinsky O, Cross J, Laux L, Marsh E, Miller I, Nabbout R, et al. Trial of cannabidiol for drugresistant seizures in the Dravet syndrome. N Engl J Med. 2017;376:2011-20. https://doi.org/10.1056/NEJMoa1611618
Stasiulewicz A, Znajdek K, Grudzień M, Pawiński T, Sulkowska JI. A guide to targeting the Endocannabinoid system in drug design. Int J Mol Sci. 2020;21:2778. https://doi.org/10.3390/ijms21082778
Dariš B, Verboten MT, Knez Ž, Ferk P. Cannabinoids in cancer treatment: Therapeutic potential and legislation. Bosn J Basic Med Sci. 2019;19:14-23. https://doi.org/10.17305/bjbms.2018.3532
Velasco G, Sánchez C, Guzmán M. Anticancer mechanisms of cannabinoids. Curr Oncol. 2016;23:S23-32. https://doi.org/10.3747/co.23.3080
Russo EB, Hohmann AG. Role of cannabinoids in pain management. En: Deer T, et al., editors. Comprehensive treatment of chronic pain by medical, interventional, and integrative approaches. New York, NY: Springer; 2013;181-97. https://doi.org/10.1007/978-1-4614-1560-2_18
Russo EB. Cannabinoids in the management of difficult to treat pain. Ther Clin Risk Manag. 2008;4:245-59. https://doi.org/10.2147/tcrm.s1928
Atalay S, Jarocka-karpowicz I, Skrzydlewskas E. Antioxidative and anti-inflammatory properties of Cannabidiol. Antioxidants (Basel). 2020;9:21. https://doi.org/10.3390/antiox9010021
Elikottil J, Gupta P, Gupta K. The analgesic potential of Cannabinoids. J Opioid Manag. 2009;5:341-57.
Boland EG, Bennett MI, Allgar V, Boland JW. Cannabinoids for adult cancer-related pain: Systematic review and meta-analysis. BMJ Support Palliat Care. 2020;10:14-24. https://doi.org/10.1136/bmjspcare-2019-002032
Häuser W, Petzke F, Fitzcharles MA. Efficacy, tolerability and safety of cannabis-based medicines for chronic pain management – An overview of systematic reviews. Eur J Pain. 2018;22:455-70. https://doi.org/10.1002/ejp.1118
van De Donk T, Niesters M, Kowal MA, Olofsen E, Dahan A, van Velzen M. An experimental randomized study on the analgesic effects of pharmaceutical-grade cannabis in chronic pain patients with fibromyalgia. Pain. 2019;160:860-9. https://doi.org/10.1097/j.pain.0000000000001464
O’Brien M, McDougall JJ. Cannabis and joints: Scientific evidence for the alleviation of osteoarthritis pain by cannabinoids. Curr Opin Pharmacol. 2018;40:104-9. https://doi.org/10.1016/j.coph.2018.03.012
Meng H, Johnston B, Englesakis M, Moulin DE, Bhatia A. Selective cannabinoids for chronic neuropathic pain: A systematic review and meta-analysis. Anesth Analg. 2017;125:1638-52. https://doi.org/10.1213/ANE.0000000000002110
Busse JW, Vankrunkelsven P, Zeng L, Fog Heen A, Merglen A, Campbell F, et al. Medical cannabis or cannabinoids for chronic pain: A clinical practice guideline. BMJ. 2021;374:2040. https://doi.org/10.1136/bmj.n2040
van Amsterdam J, Brunt T, van Den Brink W. The adverse health effects of synthetic cannabinoids with emphasis on psychosis-like effects. J Psychopharmacol. 2015;29:254-63. https://doi.org/10.1177/0269881114565142
Grigg J, Manning V, Arunogiri S, Lubman DI. Synthetic cannabinoid use disorder: An update for general psychiatrists. Australas Psychiatry. 2019;27:279-83. https://doi.org/10.1177/1039856218822749
Sidney S. Cardiovascular consequences of marijuana use. J Clin Pharmacol. 2002;42(Supl.1):64-70. https://doi.org/10.1002/j.1552-4604.2002.tb06005.x
Lee J, Sharma N, Kazi F, Youssef I, Myers A, Marmur JD, et al. Cannabis and myocardial infarction: Risk factors and pathogenetic insights. SciFed J Cardiol. 2017;1 1000004.
Samaan J, Ferrer GF, Akinyemi B, Junquera P, Oms J, Dumenigo R. Synthetic Cannabis overdose and withdrawal in a young adult: A case report, commentary on regulation, and review of the literature. Case Rep Psychiatry. 2016;2016:3640549. https://doi.org/10.1155/2016/3640549
Bowman M, Pihl RO. Cannabis: Psychological effects of chronic heavy use. A controlled study of intellectual functioning in chronic users of high potency cannabis. Psychopharmacologia. 1973;29:159-70. https://doi.org/10.1007/BF00422648
Eksborg S, Rajs J. Causes and manners of death among users of heroin, methadone,amphetamine, and cannabis in relation to postmortem chemical tests for illegal drugs. Subst Use Misuse. 2008;43:1326-39. https://doi.org/10.1080/10826080801922124
Ashton CH. Adverse effects of cannabis and cannabinoids. Br J Anaesth. 1999;83:637-49. https://doi.org/10.1093/bja/83.4.637
Hamilton I. Cannabis, psychosis and schizophrenia: Unravelling a complex interaction. Addiction. 2017;112:1653-7. https://doi.org/10.1111/add.13826
Coulston CM, Perdices M, Tennant CC. The neuropsychological correlates of cannabis use in schizophrenia: Lifetime abuse/dependence, frequency of use, and recency of use. Schizophr Res. 2007;96:169-84. https://doi.org/10.1016/j.schres.2007.08.006
Hjorthøj C, Posselt CM. Δ9-Tetrahydrocannabinol: Harmful even in low doses? Lancet Psychiatry. 2020;7:296-7. https://doi.org/10.1016/S2215-0366(20)30093-6
De Aquino JP, Sherif M, Radhakrishnan R, Cahill JD, Ranganathan M, D’Souza DC, et al. The psychiatric consequences of Cannabinoids. Clin Ther. 2018;40:1448-56. https://doi.org/10.1016/j.clinthera.2018.03.013
Wilkinson ST, Radhakrishnan R, D’Souza DC. Impact of Cannabis use on the development of psychotic disorders. Curr Addict Reports. 2014;1:115. https://doi.org/10.1007/s40429-014-0018-7
Ledezma-Morales M, Rodríguez A, Amariles P. Mercado del Cannabis medicinal en Colombia: una oportunidad para el sector salud que requiere lineamientos estratégicos del gobierno nacional y la academia. Med UIS. 2020;33:53-8.
Ramírez, J. La industria del cannabis medicinal en Colombia. Fedesarrollo. 2019. Fecha de consulta: 14 de diciembre de 2021. Disponible en: https://www.repository.fedesarrollo.org.co/bitstream/handle/11445/3823/Repor_Diciembre_2019_Ram%C3%ADrez.pdf?sequence=4&isAllowed=y
Some similar items:
- Claudia Blanco, María Ximena Núñez, Efficacy of Orbscan II® and Pentacam® topographers by a repeatability analysis when assessing elevation maps in candidates to refractive surgery , Biomedica: Vol. 29 No. 3 (2009)
- José Moreno, Fernando De la Hoz, Alejandro Rico, Karol Cotes, Alexandra Porras, Flu vaccine effectiveness: a metaanalysis , Biomedica: Vol. 29 No. 1 (2009)
- Clara Beatriz Ocampo, Gloria I. Giraldo Calderon, Mauricio Perez, Carlos A. Morales, Evaluation of the triflumuron and the mixture of Bacillus thuringiensis plus Bacillus sphaericus for control of the immature stages of Aedes aegypti and Culex quinquefasciatus (Diptera: Culicidae) in catch basins , Biomedica: Vol. 28 No. 2 (2008)
- Jaime Carmona-Fonseca, Gonzalo Álvarez, Silvia Blair, Plasmodium vivax malaria: treatment of primary attacks with primaquine, in three different doses, and a fixed dose of chloroquine, Antioquia, Colombia, 2003-2004 , Biomedica: Vol. 26 No. 3 (2006)
- Claudia Lucía Colorado, Guillermo Sánchez, Martha Inírida Guerrero, Clara Inés León, Reliability and agreement of two smear reading scales for classification and monitoring of multidrug therapy in leprosy patients , Biomedica: Vol. 31 No. 3 (2011)
- Manuel Alberto Pérez, Liliana Jazmín Cortés, Ángela Patricia Guerra, Angélica Knudson, Carlos Usta, Rubén Santiago Nicholls, Efficacy of the amodiaquine+sulfadoxine-pyrimethamine combination and of chloroquine for the treatment of malaria in Córdoba, Colombia, 2006 , Biomedica: Vol. 28 No. 1 (2008)
- Alexandra Ríos, Gonzalo Álvarez, Silvia Blair, Ten years of chloroquine efficacy for uncomplicated Plasmodium vivax malaria treatment, Turbo, Antioquia, 2002 and 2011 , Biomedica: Vol. 33 No. 3 (2013)
- Oscar Ramírez, Víctor Cárdenas, Germán Peña, Lizette Galindo-Toro, Juan Manuel Lozano, Association between the use of free base cocaine (basuco) by pregnant women and intrauterine growth retardation of newborns in Bogota, D.C., Colombia , Biomedica: Vol. 20 No. 4 (2000)
- Liliana María Zuluaga, John Camilo Hernández, Carlos Felipe Castaño, Jorge Hernando Donado, Effect of antenatal spiramycin treatment on the frequency of retinochoroiditis due to congenital toxoplasmosis in a Colombian cohort , Biomedica: Vol. 37 No. Sup.1 (2017): Suplemento 1, Alteraciones del sistema nervioso
- Marita Lardón, José Uberos, Eduardo Narbona, Does corticosteroid treatment during the pre and postnatal periods affect the neurodevelopmental outcome of premature newborns? , Biomedica: Vol. 37 No. Sup.1 (2017): Suplemento 1, Alteraciones del sistema nervioso
Copyright (c) 2022 Biomedica
This work is licensed under a Creative Commons Attribution 4.0 International License.
| Article metrics | |
|---|---|
| Abstract views | 1466 |
| Galley vies | 920 |
| PDF Views | 811 |
| HTML views | 0 |
| Other views | 109 |
